Skip to content

Effects of Etanercept on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis: The PRISTINE Trial

Effects of Etanercept on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis: The PRISTINE Trial 1

In the PRISTINE trial (NCT00663052), a post hoc analysis was conducted of the effects of etanercept therapy on cardiometabolic biomarkers in subjects with psoriasis based on diabetes status. Methods: Patients with moderate-to-severe plaque psoriasis were randomized to etanercept 50 mg once or twice weekly, double-blinded. Etanercept was not associated with any clinically relevant adverse effects on cardiometabolic biomarkers. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial) Journal of Dermatological Treatment: Vol.

Effects of Etanercept on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis: The PRISTINE Trial 2Effects of etanercept on cardiometabolic biomarkers in subjects with moderate to severe plaque psoriasis: The PRISTINE trial. 22nd World Congress of Dermatology; May 24 29, 2011; Seoul, Korea. PRISTINE Trial Data Explore Effects of ENBREL on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis. To measure and value the impact of combined etanercept (ETN) and methotrexate (MTX) therapy on work productivity in patients with early rheumatoid arthritis (RA) over 52 weeks. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.

Among patients with mild or severe psoriasis, psoriasis was considered to be at the root of 11. PRISTINE Trial Findings Demonstrate Burden of Moderate-to-Severe Plaque Psoriasis, and The Efficacy Profile of Etanercept Treatment. PsoRiasis study to assess efficacy and SafeTy IN subjects taking Etanercept 50 mg once weekly and twice weekly with adjunct therapy a multi-center, randomized, double-blind study evaluating the efficacy and safety of two dose regimens of etanercept used with adjunctive topical therapies. Additional predefined exploratory analyses of PRISTINE were conducted to evaluate the presence of several cardio-metabolic biomarkers in the randomized population. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. Studies on the management of co-morbidities and their impact on psoriasis treatment are scarce.

American Academy Of Dermatology, Summer Academy Meeting

Risk was similar in patients with severe psoriasis affecting only the skin and in those with psoriatic arthritis. 35 Nevertheless, in patients with CHF, no therapeutic effect was demonstrated in 3 clinical trials with the TNF inhibitors etanercept and infliximab,36 and in an infliximab trial mortality was higher in the group treated with infliximab 10mg/kg (a higher dose than that used in psoriasis and rheumatoid arthritis) than in the controls. Most of the experimental evidence and biomarker studies indicate a link between IL-17 and instability in atherosclerotic plaques, a finding that may partially explain the increased risk of myocardial infarction in patients with psoriasis. Baseline cardiometabolic abnormalities in subjects with moderate-to-severe plaque psoriasis in the PRISTINE trial. Phototherapy has no major cardiovascular impact and may reduce levels of proinflammatory cytokines. Most studies lack the power and randomization of large clinical trials and long-term follow-up periods. Some therapies for moderate to severe psoriasis, including methotrexate and tumor necrosis factor inhibitors, may reduce cardiovascular events in psoriatic patients. Sustained remission with etanercept tapering in early rheumatoid arthritis. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. Combination etanercept and methotrexate provides better disease control in very early ( 4 months) versus early rheumatoid arthritis ( 4 months and 2 years): post hoc analyses from the COMET study. The effect of stress on the expression of the amyloid precursor protein in rat brain. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Impact of etanercept therapy on disease activity and health-related quality of life in moderate rheumatoid arthritis patients: population from a national British obser. Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia Pavelka K, Burgos-Vargas R, Miranda P, Guzman R, Yen J, Al Izzi M, Szekanecz A, Tang B, Szumski A, Kotak S, Bananis E, Koenig AS, Mahgoub E, & Rahman M, Int.

Psoriasis Review